A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.
Bibliographic record
Abstract
e16183 Background: Significant advances have been made in the management of hepatocellular carcinoma (HCC) with the introduction of locoregional therapies including Theraspere, a treatment utilizing glass microspheres coated in radioactive yttrium-90 (Y-90). Hepatocyte exposure to Y-90 results in immunogenic cell death and tumor-specific immunity, suggesting this treatment may synergize with checkpoint inhibitor therapies to improve response rates and disease control. This abstract presents the results of combination therapy with Y-90 and NIVO in patients with advanced HCC. Methods: This study is a prospective, open-label, phase I clinical trial of NIVO plus Y-90. Eligible patients were diagnosed with advanced HCC (CP A6-B7) and were not transplant or resection candidates. Patients were treated with Y-90 following institutional procedures. The NIVO dose was escalated in a standard 3+3 format. Patients at DL1 began therapy 4 weeks after Y90 administration and received 80 mg of NIVO every two weeks. Patients at DL2 began therapy 2 weeks after Y90 administration and received 240 mg of NIVO every two weeks. The primary objective was to determine a maximum tolerated dose (MTD) of NIVO in combination with Y-90 therapy. Secondary objectives included objective response rate (RECIST v1.1), toxicity evaluation, disease control rate and progression free survival. Results: Fifteen patients were registered to DL1, 8 received Y90 and 6 were eligible and received NIVO. Twelve patients were registered to DL2, 9 were eligible for Y90, 7 were eligible for NIVO and 6 completed therapy. Patients that did not complete therapy either withdrew consent, had a decline in performance status or a worsening in hepatic function. Fifty-nine percent of patients were male (N = 10), 82% were Caucasian (N = 14), 12% were Hispanic or Latino (N = 2) and 6% were African American (N = 1). Of the patients who received both Y90 and NIVO, 82% patients were CP B7. The MTD of NIVO is 240mg given 2 weeks after Y90. The disease control rate was 82% (N = 9/11 with stable disease). Forty-six percent of patients (N = 6) had a decrease in circulating levels of AFP, the most significant change was a decrease from 11,080 ng/mL to 260 ng/mL following cycle 2 of NIVO and normalization by cycle 4 of NIVO. The most common toxicities in both treatment groups were Grade 1-2 elevations in ALT/AST, frequency of these side effects was not higher than expected given this patient population. Conclusions: Therapy with Y-90 and NIVO in advanced HCC was tolerable and a maximum tolerated dose of NIVO was established. Combination therapy resulted in a clinical benefit rate of 82%, with 9 patients achieving stable disease. In a notably sick patient population with advanced CP scores this combination offered good disease control without increasing the adverse event rate. Study was stopped early due to lack of funding. Clinical trial information: NCT02837029.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.002 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".